Indication -
Vaxelis is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to H. influenzae type b. Vaxelis approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information –
Do not administer Vaxelis to anyone with a history of severe allergic reaction to a previous dose of Vaxelis, any ingredient of Vaxelis, or any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis vaccine, or Hib vaccine.
Do not administer Vaxelis to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
Do not administer Vaxelis to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
Carefully consider benefits and risks before administering Vaxelis to persons with a history of: fever greater or equal to 40.5 degrees Celsius (greater than or equal to 105 degrees Fahrenheit), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting greater than or equal to 3 hours within 48 hours after a previous pertussis-containing vaccine, and/or seizures within 3 days after a previous pertussis-containing vaccine.
If Guillain-Barre syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barre syndrome may be increased following Vaxelis.
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant's medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer Vaxelis to an infant born prematurely.
Vaccination with Vaxelis may not protect all individuals.
The solicited adverse reactions 0-5 days following any dose were irritability (greater than or equal to 55 percent), crying (greater than or equal to 45 percent), injection site pain (greater than or equal to 44 percent), somnolence (greater than or equal to 40 percent), injection site erythema (greater than or equal to 25 percent), decreased appetite (greater than or equal to 23 percent), fever greater than or equal to 38.0 degrees Celsius (greater than or equal to 19 percent), injection site swelling (greater than or equal to 18 percent), and vomiting (greater than or equal to 9 percent).
The 3-dose immunization series consists of a .5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
A 3-dose series of Vaxelis does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.
Billing and Coding:
This list of codes may be relevant for VAXELIS and its administration. This list is current as of November 2020. The information provided here is compiled from sources believed to be accurate, but PCA makes no representation that it is accurate. This information is subject to change.
You are solely responsible for determining the appropriate codes and for any action you take in billing. The use of this information does not guarantee payment or that any payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.